search
Back to results

Physical Activity for Myeloma Autograft Longitudinal Study (PAMAL)

Primary Purpose

Physical Activity, Multiple Myeloma, Quality of Life

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Physical exercises
Optional physical exercises
Sponsored by
Centre Hospitalier Universitaire, Amiens
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Physical Activity focused on measuring physical activity, multiple myeloma, autologous stem cell transplantation, quality of life, physical conditioning

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Under 65-year-old patient
  • more than 18 years old
  • Hospitalized for autologous stem cell transplantation
  • First or second line therapy for multiple myeloma
  • Chemotherapy regimen with melphalan
  • Patient affiliated to the social security system
  • Signed informed consent form
  • Patient who have computer and internet connection at home

Exclusion Criteria:

  • Over-65-year-old patient
  • Other haematological malignancies
  • More than 2 treatment lines
  • Other regimen of chemotherapy for autograft than melphalan
  • Contraindication to physical exercises: uncontrolled arterial hypertension or diabetes, heart or respiratory failure, psycho-cognitive disorders that may compromise the physical exercises program
  • dialyzed patient
  • Adult patient under tutelage

Sites / Locations

  • CHU AmiensRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Physical exercise arm

controlled arm

Arm Description

patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice

patients will be hospitalized in the same conditions than the experimental group and will be able to practice if they want.

Outcomes

Primary Outcome Measures

Measure of quality of life with EORTC QLQ-C30 questionnaire
The quality of life will be measure with the EORTC quality QLQ-C30 questionnaire to assess the quality of life of cancer patients. Scales range in score is from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
Measure of quality of life with EORTC QLQ-C30 questionnaire
The quality of life will be measure with the EORTC quality QLQ-C30 questionnaire to assess the quality of life of cancer patients. Scales range in score is from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
Measure of quality of life with EORTC QLQ-C30 questionnaire
The quality of life will be measure with the EORTC quality QLQ-C30 questionnaire to assess the quality of life of cancer patients. Scales range in score is from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
Measure of quality of life with QLQ-MY20 questionnaire
The quality of life will be measure with the QLQ-MY20 questionnaire to assess the quality of life of cancer patients. QLQ-MY20 domain scores are averaged and transformed linearly to a score ranging from 0-100. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.
Measure of quality of life measured with QLQ-MY20 questionnaire
The quality of life will be measure with the QLQ-MY20 questionnaire to assess the quality of life of cancer patients. QLQ-MY20 domain scores are averaged and transformed linearly to a score ranging from 0-100. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.
Measure of quality of life measured with QLQ-MY20 questionnaire
The quality of life will be measure with the QLQ-MY20 questionnaire to assess the quality of life of cancer patients. QLQ-MY20 domain scores are averaged and transformed linearly to a score ranging from 0-100. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.

Secondary Outcome Measures

Measure of fatigue evaluated by Piper scale
The Piper Fatigue Scale is composed of 22 numerically scaled, "0" to "10" items that measure four dimensions of subjective fatigue. This will give an average score that remains on the same "0" to "10"numeric scale. O is the moderate score and 10 is the worst score.
Measure of fatigue evaluated by Piper scale
The Piper Fatigue Scale is composed of 22 numerically scaled, "0" to "10" items that measure four dimensions of subjective fatigue. This will give an average score that remains on the same "0" to "10"numeric scale. O is the moderate score and 10 is the worst score.
Measure of fatigue evaluated by Piper scale
The Piper Fatigue Scale is composed of 22 numerically scaled, "0" to "10" items that measure four dimensions of subjective fatigue. This will give an average score that remains on the same "0" to "10"numeric scale. O is the moderate score and 10 is the worst score.

Full Information

First Posted
May 9, 2019
Last Updated
February 7, 2023
Sponsor
Centre Hospitalier Universitaire, Amiens
Collaborators
University Hospital, Rouen, University Hospital, Caen
search

1. Study Identification

Unique Protocol Identification Number
NCT03946332
Brief Title
Physical Activity for Myeloma Autograft Longitudinal Study
Acronym
PAMAL
Official Title
Physical Exercises for Patient Undergoing Hematopoietic Stem Cell Transplantation for Multiple Myeloma: a Controlled Randomised Prospective Multicentre Longitudinal Study.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
May 1, 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire, Amiens
Collaborators
University Hospital, Rouen, University Hospital, Caen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Physical exercises program is known to improve quality of life, chronical fatigue and appears to be a behavioural recommendation against cancer as primary and tertiary prevention. Nutritional status is also important in cancer patients: a loss of 5% of weight increases the complication risks and decreases survival and the quality of life. Interactions between physical activity and haematological malignancies are less described compared to solid cancers. Methodology and protocols are also heterogeneous. Supervised exercises program improves the physical condition and the quality of life; however there are few randomised studies versus a controlled group. Post autograft evaluation for myeloma patients showed a physical deficit with increased fat mass, but in this particular population physical exercises need to be more explored. This project is a randomised study versus controlled group that evaluates supervised physical exercises program in a homogenous population: patients under-65-years-old with multiple myeloma and who will undergo autologous stem cell transplantation.
Detailed Description
Physical exercises program is known to improve quality of life, chronical fatigue and appears to be a behavioural recommendation against cancer as primary and tertiary prevention. Nutritional status is also important in cancer patients: a loss of 5% of weight increases the complication risks and decreases survival and the quality of life. Interactions between physical activity and haematological malignancies are less described compared to solid cancers. This multicentre project is a randomised study versus controlled group that evaluates supervised physical exercises program in a homogenous population: patients under-65-years-old with multiple myeloma and who will undergo autologous stem cell transplantation. The hypothesis of this study is that a supervised physical exercises program during and after autograft might have a positive impact on the physical capacities and the quality of life. In the experimental arm, patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice. In the controlled arm, patients will be hospitalized in the same conditions than the experimental group and can practice if they want. At the end of the hospitalization, they will receive a paper document with global informations about physical exercises including a few simple exercises. Evaluations will be carried out in both arms at day 0, day 30 and day 90 from autograft. The post graft follow up will be done at the same time as the medical consultation and before the maintenance treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Physical Activity, Multiple Myeloma, Quality of Life
Keywords
physical activity, multiple myeloma, autologous stem cell transplantation, quality of life, physical conditioning

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Physical exercise arm
Arm Type
Experimental
Arm Description
patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice
Arm Title
controlled arm
Arm Type
Active Comparator
Arm Description
patients will be hospitalized in the same conditions than the experimental group and will be able to practice if they want.
Intervention Type
Behavioral
Intervention Name(s)
Physical exercises
Intervention Description
patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
Intervention Type
Behavioral
Intervention Name(s)
Optional physical exercises
Intervention Description
patients will be proposed for the physical exercises and will practice them if they want.
Primary Outcome Measure Information:
Title
Measure of quality of life with EORTC QLQ-C30 questionnaire
Description
The quality of life will be measure with the EORTC quality QLQ-C30 questionnaire to assess the quality of life of cancer patients. Scales range in score is from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
Time Frame
at day 0 from autograft as patient will be hospitalized.
Title
Measure of quality of life with EORTC QLQ-C30 questionnaire
Description
The quality of life will be measure with the EORTC quality QLQ-C30 questionnaire to assess the quality of life of cancer patients. Scales range in score is from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
Time Frame
at day 30 from autograft as patient will be hospitalized.
Title
Measure of quality of life with EORTC QLQ-C30 questionnaire
Description
The quality of life will be measure with the EORTC quality QLQ-C30 questionnaire to assess the quality of life of cancer patients. Scales range in score is from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
Time Frame
at day 90 from autograft as patient will be hospitalized.
Title
Measure of quality of life with QLQ-MY20 questionnaire
Description
The quality of life will be measure with the QLQ-MY20 questionnaire to assess the quality of life of cancer patients. QLQ-MY20 domain scores are averaged and transformed linearly to a score ranging from 0-100. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.
Time Frame
at day 0 from autograft as patient will be hospitalized.
Title
Measure of quality of life measured with QLQ-MY20 questionnaire
Description
The quality of life will be measure with the QLQ-MY20 questionnaire to assess the quality of life of cancer patients. QLQ-MY20 domain scores are averaged and transformed linearly to a score ranging from 0-100. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.
Time Frame
at day 30 from autograft as patient will be hospitalized.
Title
Measure of quality of life measured with QLQ-MY20 questionnaire
Description
The quality of life will be measure with the QLQ-MY20 questionnaire to assess the quality of life of cancer patients. QLQ-MY20 domain scores are averaged and transformed linearly to a score ranging from 0-100. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.
Time Frame
at day 90 from autograft as patient will be hospitalized.
Secondary Outcome Measure Information:
Title
Measure of fatigue evaluated by Piper scale
Description
The Piper Fatigue Scale is composed of 22 numerically scaled, "0" to "10" items that measure four dimensions of subjective fatigue. This will give an average score that remains on the same "0" to "10"numeric scale. O is the moderate score and 10 is the worst score.
Time Frame
at day 0 from autograft as patient will be hospitalized.
Title
Measure of fatigue evaluated by Piper scale
Description
The Piper Fatigue Scale is composed of 22 numerically scaled, "0" to "10" items that measure four dimensions of subjective fatigue. This will give an average score that remains on the same "0" to "10"numeric scale. O is the moderate score and 10 is the worst score.
Time Frame
at day 30 from autograft as patient will be hospitalized.
Title
Measure of fatigue evaluated by Piper scale
Description
The Piper Fatigue Scale is composed of 22 numerically scaled, "0" to "10" items that measure four dimensions of subjective fatigue. This will give an average score that remains on the same "0" to "10"numeric scale. O is the moderate score and 10 is the worst score.
Time Frame
at day 90 from autograft as patient will be hospitalized.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Under 65-year-old patient more than 18 years old Hospitalized for autologous stem cell transplantation First or second line therapy for multiple myeloma Chemotherapy regimen with melphalan Patient affiliated to the social security system Signed informed consent form Patient who have computer and internet connection at home Exclusion Criteria: Over-65-year-old patient Other haematological malignancies More than 2 treatment lines Other regimen of chemotherapy for autograft than melphalan Contraindication to physical exercises: uncontrolled arterial hypertension or diabetes, heart or respiratory failure, psycho-cognitive disorders that may compromise the physical exercises program dialyzed patient Adult patient under tutelage
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie Beaumont, MD
Phone
(33)322455914
Email
beaumont.marie@chu-amiens.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Quentin Vacandare, Pr
Phone
(33)322456443
Email
vacandare.quentin@chu-amiens.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
caroline delette, MD
Organizational Affiliation
CHU Amiens
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pierre Morel, MD
Organizational Affiliation
CHU Amiens
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Fabrice Jardin, Pr
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Oana Brehar, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Vincent Camus, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nathalie Cardinael, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nathalie Contentin, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marie-Laure Fontoura, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carole Fronville Varnier, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hélène Lanic, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Emilie Lemasle Hue, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pascal Lenain, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stéphane Lepretre, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anna-Lise Menard, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Aspasia Stamatoullas-Bastard, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hervé Tilly, MD
Organizational Affiliation
CHU Rouen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gandhi L Damaj, Pr
Organizational Affiliation
CHU Caen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stéphane Cheze, MD
Organizational Affiliation
CHU Caen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Margaret Macro, MD
Organizational Affiliation
CHU Caen
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Amiens
City
Amiens
ZIP/Postal Code
80054
Country
France
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Physical Activity for Myeloma Autograft Longitudinal Study

We'll reach out to this number within 24 hrs